Contemplated Use Clause Samples

Contemplated Use. Without in any way being limited by the specificity of the foregoing, the District, in its sole discretion, is satisfied that there are no matters which would prohibit or unreasonably interfere with the use of the Project for its intended purpose.
Contemplated Use. Please use the following space to provide a project description of the research including contemplated use of the St. Jude Data, that constitutes biomedical research. Include information about what research question you will be investigating and how the requested data will aid in your research. Add blank pages as needed (150 words or more): For and on behalf of User*: * All who will have access to the Data must be listed as an applicant below; please attach additional pages as needed. Signatories must include Laboratory Head, Principal Investigator, or Departmental Chair. The Principal Investigator and other applicants and signatories agree to the terms in this AGREEMENT FOR ACCESS AND/OR DOWNLOAD OF CONTROLLED-ACCESS GENOMIC SEQUENCING DATA, and shall inform other investigators and laboratories in his or her institution who may have or desire access to the Data as defined in this Agreement of the restrictions of this Agreement. The Principal Investigator is signing on behalf of himself or herself, and those in his/her laboratory or on his/her project but does not sign on behalf of the User Institution unless so authorized by the User Institution.
Contemplated Use. The term "Contemplated Use" shall mean a full service restaurant consistent with the prototypical design of Buyer's restaurants, containing a minimum of 220 seats and with a liquor license allowing the sale of beer, wine and alcoholic beverages for consumption on site.
Contemplated Use does not and will not infringe upon any intellectual property rights or any other rights of any other Person.
Contemplated Use. The Premises may be used for general office purposes, printing or copying business, warehousing, wholesale distribution, light manufacturing, assembly business, or any other lawful business.
Contemplated Use. The Contemplated Use for the Site is consistent with its prior commercial/industrial use as a galvanizing facility. Contemplated use includes (without limiting the foregoing sentence) galvanizing operations within a covered structure of approximately 24,700 square feet; zinc recovery operations under covered roof; light maintenance in a shop building and administrative functions in an office/break building.
Contemplated Use. The parties expressly acknowledge that the Real Property parcels identified in Exhibit A to the Contract may not, in each case, be a suitable development site and Seller, Owner and Purchaser are hereby released from any specific obligation to convey or acquire those specific parcels. In the event one or more Target Seller Resort(s) site is identified and agreed upon, then the conveyance of such site(s) shall be on the terms and conditions set forth in the Contract, with such exceptions as may be agreed to by Purchaser in site-specific agreements contemplated in Section 2.1 hereof, including, without limitation, being subject only to the Permitted Exceptions and the restrictions set forth in the Contract.

Related to Contemplated Use

  • Permitted Use (a) Tenant shall, at all times during the Term, and at any other time that Tenant shall be in possession of any Property, continuously use and operate, or cause to be used and operated, such Property as a skilled nursing/ intermediate care/independent living/assisted living/ special care/group home facility as currently operated, and any uses incidental thereto. Tenant shall not use (and shall not permit any Person to use) any Property, or any portion thereof, for any other use without the prior written consent of Landlord, which approval shall not be unreasonably withheld, delayed or conditioned. No use shall be made or permitted to be made of any Property and no acts shall be done thereon which will cause the cancellation of any insurance policy covering such Property or any part thereof (unless another adequate policy is available) or which would constitute a default under any ground lease affecting such Property, nor shall Tenant sell or otherwise provide to residents or patients therein, or permit to be kept, used or sold in or about any Property any article which may be prohibited by law or by the standard form of fire insurance policies, or any other insurance policies required to be carried hereunder, or fire underwriter’s regulations. Tenant shall, at its sole cost (except as expressly provided in Section 5.1.2(b)), comply or cause to be complied with all Insurance Requirements. Tenant shall not take or omit to take, or permit to be taken or omitted to be taken, any action, the taking or omission of which materially impairs the value or the usefulness of any Property or any part thereof for its Permitted Use. (b) In the event that, in the reasonable determination of Tenant, it shall no longer be economically practical to operate any Property as currently operated, Tenant shall give Landlord Notice thereof, which Notice shall set forth in reasonable detail the reasons therefor. Thereafter, Landlord and Tenant shall negotiate in good faith to agree on an alternative use for such Property, appropriate adjustments to the Additional Rent and other related matters; provided, however, in no event shall the Minimum Rent be reduced or abated as a result thereof. If Landlord and Tenant fail to agree on an alternative use for such Property within sixty (60) days after commencing negotiations as aforesaid, Tenant may market such Property for sale to a third party. If Tenant receives a bona fide offer (an “Offer”) to purchase such Property from a Person having the financial capacity to implement the terms of such Offer, Tenant shall give Landlord Notice thereof, which Notice shall include a copy of the Offer executed by such third party. In the event that Landlord shall fail to accept or reject such Offer within thirty (30) days after receipt of such Notice, such Offer shall be deemed to be rejected by Landlord. If Landlord shall sell the Property pursuant to such Offer, then, effective as of the date of such sale, this Agreement shall terminate with respect to such Property, and the Minimum Rent shall be reduced by an amount equal to the product of the net proceeds of sale received by Landlord multiplied by the Interest Rate. If Landlord shall reject (or be deemed to have rejected) such Offer, then, effective as of the proposed date of such sale, this Agreement shall terminate with respect to such Property, and the Minimum Rent shall be reduced by an amount equal to the product of the projected net proceeds determined by reference to such Offer multiplied by the Interest Rate.

  • Intended Use Customer will use Software in accordance with its intended use, instructions for use and all applicable Software labeling as described in the Documentation and the Offer. Customer is responsible for ensuring that the way that it uses Software complies with all applicable laws and regulations.

  • Restricted Use Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Adalimumab (Humira® / Biosimilar) NHSE Children with Severe Refractory Uveitis with onset in childhood (age 2 or more up to 18 or less) - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Adalimumab (biosimilar) (Imraldi® / Amjevita®) ICB Peripheral spondyloarthritis - following use of 3 DMARDs, as per local pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Adalimumab (biosimilar) various ICB weekly use for dose escalations in NICE-approved rheumatology indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Adefovir Hepsera ® NHSE Hepatitis B Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG165 - Oct 17 Double Red ADHD drugs - various (Various) ICB First-line use in children and adolescents with ADHD - as per NICE CG 72 - Do Not Do (Not a licensed indication). Not recommended for routine use - Specialist initiation only CG72 - Feb 16 Double Red ADHD drugs - various (Various) ICB Use in pre-school children - as per NICE CG 72 - Do Not Do (Not a licensed indication). Not recommended for routine use - Specialist initiation only CG72 - Feb 16 BLACK Afamelanotide Scenesse® NHSE erythropoietic protoporphyria Not commissioned. No NHS prescribing in primary or secondary care HST27 – July 2023 Hospital Afatinib ▼ (Giotrif® ▼) NHSE Treatment of epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer - as per NICE TA 310 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA310 - April 2014 BLACK Afatinib ▼ (Giotrif® ▼) NHSE Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy - as per NICE TA 444 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA444 - May 17 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Aflibercept (Eylea®) ICB Treatment of Wet Age-related Macular Degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 Hospital Aflibercept (Eylea®) ICB Wet Age-related Macular Degeneration (AMD) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 Hospital Aflibercept (Eylea®) ICB Wet Age-related Macular Degeneration (AMD) in new patients Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 Hospital Aflibercept (Eylea®) ICB Visual impairment caused by macular oedema secondary to central retinal vein occlusion (CRVO) - as per NICE TA 305 and local treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA305 - Feb 14 BLACK Aflibercept (Zaltrap®) NHSE Treatment of metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (along with irinotecan and fluorouracil- based therapy) - as per NICE TA 307 - NICE Do Not Do Not commissioned. No NHS prescribing in primary or secondary care TA307 - Mar 14 Hospital Aflibercept (Eylea®) ICB Treatment of visual impairment caused by diabetic macular oedema (DMO) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA346 - Jul 15 Hospital Aflibercept (Eylea®) ICB Visual impairment caused by macular oedema after branch retinal vein occlusion - as per NICE TA 409 and local treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA409 - Sep 16 Hospital Aflibercept (Eylea®) ICB Treatment of visual impairment due to myopic choroidal neovascularisation in adults - as per NICE TA 486 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA486 - Nov 17 Hospital Aflibercept (Eylea®) ICB Treatment of Diabetic Macular Oedema (DMO) as part of a treat and extend regimen in line with the locally commissioned treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Aflibercept (Eylea®) ICB Treatment of Wet Age-related Macular Degeneration (AMD) as part of a treat and extend regimen in line with the locally commissioned treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Aflibercept (switched to Ranibizumab (Lucentis®) (Eylea®) ICB Switching between products in the treatment of Wet Age-related Macular Degeneration (AMD) in previously treated patients who have not responded adequately to, or who have intolerance to aflibercept (Eylea®) - as per locally commissioned pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NG82 - Jan 18 Hospital Agalsidase alfa and beta (Replagal® (alpha) / Fabrazyme® (beta)) NHSE Fabry disease (α-galactosidase A deficiency) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Agomelatine (Valdoxan®) ICB 4th line use in depression where other treatments have failed or not been tolerated (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA231 - Sep 11 Hospital Albumin bound paclitaxel Abraxane ® NHSE with gemcitabine for untreated metastatic pancreatic cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA476 - Sep 17 Hospital Albutrenpenonacog alfa (Idelvion) NHSE Haemophilia B - as per NHS England policy SSC1652 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. DM Albutropin NHSE Adult onset growth hormone deficiency . Discontinued Medicines NICE has not issued any guidance. Hospital Aldesleukin (Proleukin) NHSE Cancer - metastatic renal cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Alectinib (Alecensa®) NHSE Untreated ALK-positive advanced non- small-cell lung cancer - as per NICE TA 536 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA536 - Aug 18 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Alectinib ▼ (Alecensa® ▼) NHSE Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - as per NICE TA 438 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA438 - Mar 17 Hospital Alemtuzumab (Lemtrada®) NHSE Chronic lymphocytic leukaemia (CLL) as per NHS England policy 2013 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Alemtuzumab (Lemtrada®) NHSE Pre-transplant immunosuppression Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Alemtuzumab (MabCampath®) NHSE Behcet's syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Alemtuzumab ▼ (Lemtrada® ▼) NHSE Treatment of adults with relapsing- remitting multiple sclerosis (RRMS) - as per NICE TA 312 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA312 - May 14 Double Red Alendronate / Vitamin D3 combination (Fosavance®) ICB Treatment of post menopausal osteoporosis in women at risk of vitamin D deficiency Not recommended for routine use NICE has not issued any guidance. GREEN Alendronic acid (sodium alendronate) (Generics available) ICB Secondary prevention of osteoporotic fragility fractures in postmenopausal women - as per NICE criteria Formulary - Drugs that can be initiated by Prescriber in Primary Care TA161 - Oct 08 GREEN Alendronic acid (sodium alendronate) (Generic available) ICB Primary prevention of osteoporotic fragility fractures in postmenopausal women as per NICE criteria Formulary - Drugs that can be initiated by Prescriber in Primary Care TA464 - Aug 17 ADVICE Alfacalcidol (AlfaD®, One- Alpha®) ICB Preparation for hyperparathyroidectomy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Hospital Alglucosidase alfa (Myozyme®) NHSE Pompe disease (a lysosomal storage disorder caused by deficiency of acid alpha-glucosidase) - as per NHS England Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Alimemazine (Trimeprazine) (Generics) ICB Sedative in children / general antihistamine Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Alipogene tiparvovec (Glybera®) NHSE (Gene therapy treatment for ) Lipoprotein lipase deficiency - as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Alirocumab ▼ (Praluent® ▼) ICB Treating primary hypercholesterolaemia and mixed dyslipidaemia - as per NICE TA 393 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA393 - Jun 16 BLACK Aliskiren ▼ (Rasilez® ▼) ICB Treatment of essential hypertension - as per NICE CG 127 Not commissioned. No NHS prescribing in primary or secondary care CG127 - Sep 11 Double Red Alisporivir ((aka Debio 025 / DEB025 / UNIL- 025)) NHSE Viral Hepatitis C - as per NHSE policy Not recommended for routine use NICE has not issued any guidance. Hospital Alitretinoin (Toctino®) ICB Treatment of severe chronic hand eczema - as per NICE TA 177 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA177 - Aug 09 BLACK Alpelisib Piqray® NHSE with fulvestrant for treating hormone- receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA652 – October 2020 Hospital Alpelisib Piqray® NHSE with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA816 – August 2022 Double Red Alpha blockers - various (Various) ICB Treatment of cor pulmonale - as per NICE CG 101 . Not recommended for routine use CG101 - Jul 10 Hospital Alpha-mannosidase - recombinant human (Lamazym®) NHSE Alpha Mannosidase deficiency - as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Alprostadil cream (Vitaros®) ICB Erectile dysfunction (as per SLS conditions only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Alteplase (Actilyse®) ICB Treatment of acute ischaemic stroke - as per NICE TA 264 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA264 - Sep 12 Double Red Amantadine Hydrochloride (Lysovir®) ICB Treatment and prophylaxis of influenza Not recommended for routine use TA168 - Feb 09 Hospital Ambrisentan (Volibris® ▼) NHSE Pulmonary Arterial Hypertension - specialist centre only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Amifampridine (phosphate) ▼ (Firdapse® ▼) NHSE Treatment of myasthenias - ▇▇▇▇▇▇▇- ▇▇▇▇▇ syndrome - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Amikacin - liposomal for inhalation (Arikace®) NHSE Gram-negative bacterial infection in Cystic Fibrosis . Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Amikacin (for inhalation) (Amikin®) NHSE Gram-negative bacterial infection in Cystic Fibrosis Not recommended for routine use NICE has not issued any guidance. BLACK Aminobenzoic acid (capsules and powder) (Potaba®) ICB Peyronie's disease, Scleroderma Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. AMB 2 Amiodarone (Cordarone X®) ICB Supraventricular and ventricular arrhythmias Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly CG180 - Jun 14 BLACK Amivantamab n/a NHSE EGFR exon 20 insertion mutation- positive advanced non-small-cell lung cancer after platinum-based chemotherapy Not commissioned. No NHS prescribing in primary or secondary care TA850 – December 2022 BLACK Amorolfine (Loceryl and other equivalent preparations) ICB Fungal nail infections Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Amphotericin B, itraconazole & voriconazole (Various) NHSE Chronic Pulmonary Aspergillosis (CPA) - specialist centre only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Anabasum NHSE Scleroderma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB Anagrelide ▼ (Xagrid® ▼ / Agrelin® / Agrylin®) ICB Thrombocythaemia Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. Hospital Anakinra Kineret® NHSE Still’s disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA685 – March 2021 Hospital Anakinra (Kineret®) NHSE Cryopyrin-associated periodic syndrome (CAPS) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Anakinra (Kineret®) NHSE Adult onset Still's disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Anakinra (Kineret®) NHSE Rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NG100 - Oct 2020 Hospital Anakinra (Kineret®) NHSE Juvenile Idiopathic Arthritis (JIA) Res

  • Contemplated Transactions “Contemplated Transactions” shall mean the Merger and the other transactions contemplated by the Agreement.

  • Conduct of the Business From the date hereof until the Closing or the termination of this Agreement in accordance with Section 7.1, Seller shall cause the Transferred Companies to: (x) conduct the Business in all material respects in the ordinary course consistent with past practice; and (y) use their reasonable best efforts to preserve intact the Business and the current relationships and goodwill of the Transferred Companies with customers, suppliers, contractors, licensors, employees, agents, producers, distributors, insureds, Insurance Regulators and others having business dealings with them. Without limiting the generality of the foregoing, from the date hereof until the Closing or the termination of this Agreement in accordance with Section 7.1, except as otherwise expressly permitted or required by this Agreement or as set forth in Section 4.1 of the Seller Disclosure Letter, without the prior written consent of Buyer (which consent shall not be unreasonably withheld, conditioned or delayed), Seller shall cause the Transferred Companies not to: (a) (i) split, combine or reclassify any of its outstanding capital stock or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for shares of its outstanding capital stock or (ii) purchase, redeem or otherwise acquire any shares of outstanding capital stock of the Transferred Companies or any rights, warrants or options to acquire any such shares, other than, in each case, any such transaction solely involving Transferred Companies following which each Transferred Company remains a direct or indirect wholly owned Subsidiary of Seller; (b) issue, sell, grant, pledge or otherwise encumber any shares of capital stock of any of the Transferred Companies, any other voting securities or any securities convertible into, or any rights, warrants or options to acquire, any such shares, voting securities or convertible securities, other than, in each case, any such transaction solely involving Transferred Companies following which each Transferred Company remains a direct or indirect wholly owned Subsidiary of Seller; (c) amend its Organizational Documents in a manner that would be adverse to Buyer’s interests; (d) sell, lease, license or otherwise dispose of (including by way of reinsurance) any of the material assets (other than Investment Assets, which are the subject of clause (y) of this Section 4.1) of any of the Transferred Companies, except in the ordinary course of business consistent with past practice; (e) enter into any Contract with respect to any merger, consolidation, liquidation, dissolution or business combination (including any acquisition of assets or liabilities comprising a business or a segment, division or line of business) involving any of the Transferred Companies; (f) purchase, sell, lease, pledge, exchange, encumber or otherwise dispose or acquire any property or assets (other than transactions occurring in the ordinary course of business consistent with past practice and other than Investment Assets, which are the subject of clause (y) of this Section 4.1) for which the aggregate consideration paid or payable in any individual transaction is in excess of $2,000,000 or in the aggregate in excess of $7,500,000; (g) (i) amend, extend, renew or otherwise modify in any material respect any of the Leases, (ii) assign or sublease any material portion of any of the Leased Real Property or (iii) enter into any new lease, terminate any lease or buy any real property; (i) modify or amend in any material respect or terminate any material Contract, (ii) waive, release or assign any material rights or claims under any material Contract or (iii) enter into any material Contract, in each case other than in the ordinary course of business consistent with past practice; or (x) modify, amend or terminate any OB Contract or (y) waive, release or assign any rights or claims under any OB Contract; (i) incur any financial Indebtedness for borrowed money from third party lending sources (other than current trade accounts payable incurred in respect of property or services purchased in the ordinary course of business consistent with past practice) or assume, grant, guarantee or endorse, pledge or otherwise secure any assets or property or otherwise as an accommodation become responsible for (whether primary or secondary) the obligations of any Person (other than a Transferred Company), or make any third party loans or advances (other than, in each case, in the ordinary course of business consistent with past practice), for individual amounts in excess of $1,000,000 or in the aggregate in excess of $2,000,000; (j) default under any Indebtedness, or fail to pay or satisfy when due any Liability, of any of the Transferred Companies in excess of $500,000 (other than any such Liability that is being contested in good faith); (k) forgive, cancel or compromise any material debt or claim or waive or release any right, in each case other than in the ordinary course of business consistent with past practice or pursuant to an Insurance Contract; (l) enter into any new line of business; (m) make any capital expenditures in excess of $2,000,000 individually or $5,000,000 in the aggregate (not including those made in the ordinary course of business); (n) voluntarily abandon any material Permit, except to the extent required in order to comply with applicable Law, or voluntarily terminate, fail to renew or permit to lapse any material Permit; (o) settle or compromise or agree to the dismissal of any Litigation or threatened Litigation (in each case, except for claims under any insurance policies within applicable policy limits that do not allege bad faith), other than any settlement or compromise that involves solely cash payments of less than $5,000,000 in any individual case or of less than $10,000,000 in the aggregate (provided that Seller shall provide prior written notice to Buyer of any such settlement or compromise that involves solely cash payments in excess of $2,000,000 in any individual case); (p) other than in the ordinary course of business consistent with past practice, dispose of, permit to lapse, abandon, dedicate to the public domain, waive, release or assign any rights, or settle any claims, or permit the creation of any material Lien with respect to any Intellectual Property material to the Business; (q) (i) establish, adopt, amend or terminate any Company Benefit Plan or any arrangement which upon its establishment or adoption would constitute a material Company Benefit Plan or (ii) materially amend or terminate any related material insurance policy or related material vendor contract, in either case except (A) in the ordinary course of business consistent with past practice or (B) as may be required by applicable Laws or pursuant to the terms of any Company Benefit Plan as in effect on the date hereof; (r) make or promise to make any material bonus, profit-sharing or similar payment, or fund, increase or accelerate the vesting, payment or amount of wages, salary, commissions, fringe benefits, severance benefits, deferred compensation or other compensation or benefits (including equity-based compensation, whether payable in cash or otherwise) or remuneration payable to, or for the benefit of, any Employee, in each case except (i) as required by applicable Law or the terms of any Company Benefit Plan as in effect on the date hereof and (ii) with respect to Employees other than the LTIP Employees, to the extent such action is (x) not material or (y) made in the ordinary course of business consistent with past practice (including in connection with promotions and employee review cycles consistent with past practice); (i) terminate the employment of any Key Employee (other than for cause) or hire any new employee who would be, upon hiring, a Key Employee or (ii) enter into a collective bargaining agreement or similar labor agreement with respect to any Employees or renew, extend or renegotiate any existing collective bargaining agreement or similar labor agreement with respect to any Employees, except, in the case of this clause (ii), as may be required by applicable Law; (i) settle or compromise any Tax Audit or forgo the right to any refund of Taxes; (ii) change any of the Transferred Companies’ methods, policies or practices of Tax accounting or methods of reporting income or deductions for Tax purposes from those employed in the preparation of its most recently filed Tax Return; (iii) amend any Tax Return of or with respect to any of the Transferred Companies; (iv) enter into any agreement with a Tax Authority with respect to any Transferred Company, or terminate any agreement entered into with a Tax Authority with respect to any Transferred Company that is in effect as of the date hereof; (v) alter or make any Tax election; (vi) request a ruling relating to Taxes; (vii) grant any power of attorney relating to Tax matters; or (viii) prepare any Tax Return in a manner that is not consistent with past practices; (u) terminate, cancel or amend, or cause the termination, cancellation or amendment of, any material insurance coverage (and any surety bonds, letters of credit, cash collateral or other deposits related thereto required to be maintained with respect to such coverage) maintained by the Transferred Companies that is not replaced by comparable insurance coverage; (v) change in any material respect the terms for, or policies with respect to, the payment of commissions to any of its insurance agents, brokers or producers; (w) enter into any reinsurance commutations (other than as contemplated by Section 4.16 and the Commutation Agreement), or enter into, amend, modify or otherwise revise any reinsurance agreement or treaty that results in a material change in risk or coverage; (x) make any material change in its underwriting, reinsurance, claims administration, selling, reserving, Tax or financial accounting policies, guidelines, practices or principles (other than any change required by a change in applicable Laws, GAAP or SAP or, in respect of underwriting or claims administration policies, guidelines, practices or principles, in the ordinary course of business consistent with past practice); (y) other than as set forth in Schedule 4.1(y), amend or otherwise change the Investment Guidelines or make any investment or manage its Investment Assets other than in compliance with the Investment Guidelines; (z) during the period from the date hereof to the Closing Date, spend less than 90% (without the consent of Buyer) or more than 100% (without the consent of Seller), in the aggregate, of the advertising spending called for during such period by the advertising plan set forth on Schedule 4.1(z) (for purposes of calculating such aggregate percentage, the spending called for in any period by such advertising plan that is not fully completed between the date hereof and the Closing Date shall be determined on a pro rata basis based on the number of days of such partial period that actually elapsed between the date hereof and the Closing Date), with the actual amount of such spending within such limits being determined by the management of the Transferred Companies in its sole discretion; or (aa) agree or commit to do any of the foregoing.